Pulmonary Hypertension No Bar to Single-Lung TransplantPulmonary Hypertension No Bar to Single-Lung Transplant

Pulmonary hypertension (PH) does not significantly affect outcome of single-lung transplantation, possibly increasing the number of potential recipients, according to Wisconsin-based researchers. Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Transplantation News Source Type: news

Related Links:

This article reports a rare coexistence of aberrant right subclavian artery with other congenital anomalies of the heart and great vessels in living men.
Source: Surgical and Radiologic Anatomy - Category: Anatomy Source Type: research
Publication date: Available online 6 February 2019Source: The Lancet Respiratory MedicineAuthor(s): Peter M George, Caroline M Patterson, Anna K Reed, Muhunthan ThillaiSummaryIdiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis. Lung transplantation is the only intervention shown to increase life expectancy for patients with IPF, but it is associated with disease-specific challenges. In this Review, we discuss the importance of a proactive approach to the management of IPF comorbidities, including gastro-oesophageal reflux, pulmonary hypertension, coronary artery disease, and malignancy. ...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Idiopathic pulmonary hypertension (IPH) is an indication for lung transplantation (LTx) or combined heart ‒lung transplantation (HLTx) in the pediatric population. Overall, pulmonary vascular disease is the primary diagnosis for a large minority of children listed for lung transplant, especially those
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: RESEARCH CORRESPONDENCE Source Type: research
Idiopathic pulmonary hypertension (IPH) is an indication for lung transplantation (LTx) or combined heart-lung transplantation (HLTx) in the pediatric population. Overall, pulmonary vascular disease is the primary diagnosis for a large minority of children listed for lung transplant, especially those less than 6 years of age.1 However, the relatively low numbers of these surgical procedures performed in children limits accurate outcome data. Previously published work has included study cohorts ranging from 5 to 23 children, severely restricting the ability to predict post-thoracic transplant outcomes based on clinical characteristics.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Research Correspondence Source Type: research
Abstract Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension (PH). The prognosis of PVOD patients remains poor, since no effective medical therapy is yet available. Imatinib is a tyrosine kinase inhibitor specific for platelet-derived growth factor receptor and is expected as a treatment option for pulmonary arterial hypertension (PAH). Recently, it has been reported that imatinib improved functional capacity of a patient with PVOD. We here report a patient with suspected PVOD who has been successfully treated with imatinib and is alive for 6 years after diagnosis. A 57-year-old woman ...
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
The number of heart and lung transplantations has risen over the years, and they remain the mainstay of treatment for end-stage heart failure and end-stage lung diseases. From the assessment of the donor's heart to intraoperative management during separation from cardiopulmonary bypass (CPB) to the postoperative follow-up of heart transplant patients, echocardiography plays a vital role throughout this process. Patients with chronic lung diseases also may have cardiovascular compromise secondary to pulmonary hypertension, pre-existing coronary artery disease, or valvular heart disease.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Review Article Source Type: research
Tedford RJ, Beaty CA, Mathai SC, Kolb TM, Damico R, Hassoun PM, Leary PJ, Kass DA, Shah AS.   Prognostic value of the pre-transplant diastolic pulmonary artery pressure–to–pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension.  J Heart Lung Transplant 2014;33(3):289-97.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification ap...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: World Symposium on Pulmonary Hypertension Source Type: research
Intensive care of patients with pulmonary hypertension (PH) and right-sided heart failure includes treatment of factors causing or contributing to heart failure, careful fluid management, and strategies to reduce ventricular afterload and improve cardiac function. Extracorporeal membrane oxygenation (ECMO) should be considered in distinct situations, especially in candidates for lung transplantation (bridge to transplant) or, occasionally, in patients with a reversible cause of right-sided heart failure (bridge to recovery). ECMO should not be used in patients with end-stage disease without a realistic chance for recovery ...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: World Symposium on Pulmonary Hypertension Source Type: research
END-STAGE PULMONARY hypertension and right ventricular (RV) dysfunction are common in patients presenting for orthotopic lung transplantation (LT), occurring in approximately 25% of patients referred for LT.1,2 It therefore is prudent to consider hemodynamic support options in this population. Cardiopulmonary support may be required in 30% to 40% of patients undergoing LT, although this may vary by institutional practice and individual patient risk factors.3 –6 This extracorporeal support may be indicated in cases of pulmonary hypertension, right ventricular (RV) failure, or the inability to tolerate one lung ventila...
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Case Report Source Type: research
More News: Health | Hypertension | Lung Transplant | Pulmonary Hypertension | Transplant Surgery | Transplants